NEW YORK, May 29, 2026, 19:03 EDT
Shares of INVO Fertility Inc. traded sharply higher late Friday, with the stock most recently at $1.88, up 14.1%. The Nasdaq ticker saw a range between $1.67 and $2.97 during the session and volume reached roughly 12.3 million shares. Latest market cap was around $6.5 million.
INVO shares moved as the company remains late on important financial filings. The company said in a May 18 filing it hadn’t finished its March-quarter 10-Q because it was still working on the 2025 10-K, an annual report with audited numbers. The same filing, signed by CEO Steve Shum, said INVO was trying to finish both reports “as promptly as practicable.”
Nasdaq told INVO on April 23 that it was out of compliance with Listing Rule 5250(c)(1) because it missed a required filing. INVO said the notice does not affect its listing right now, and its shares still trade as IVF. Nasdaq gave the company 60 days from the notice to file a plan to regain compliance, and allowed for a possible extension out to Oct. 13, 2026.
INVO hasn’t put out new financials since the May 18 late-filing notice, according to SEC archive records. So traders still don’t have audited 2025 results or Q1 2026 numbers. The stock has seen big swings.
INVO calls itself a healthcare services fertility company aiming to grow access to assisted reproductive technology, or ART, which covers treatments like in vitro fertilization. In April, the company reported it had four U.S. fertility clinics running and that it sells INVOcell, a device for intravaginal culture, where early embryo development happens inside the body instead of a lab incubator.
INVO went through a 1-for-5 reverse split on March 27, cutting the share count and lifting the price per share. The split doesn’t change INVO’s overall value, but it does make straight price comparisons tricky.
But there are risks for the rally. INVO’s most recent annual report flagged “substantial doubt” about its ability to keep operating, citing its finances. The company also pointed out its stock trades thinly and can be volatile. Its annual report is delayed, Nasdaq compliance is still unresolved, and the shares are microcap. Thin liquidity can help fuel a move up, but also makes it tough to get out.
The action set the stock apart from other fertility names. Progyny slipped 0.5% to $25.56. CooperCompanies, which includes the CooperSurgical unit, added 0.3% at $61.21.
Stocks in the U.S. finished up Friday. The S&P 500 edged up 0.22%, the Dow gained 0.72%, and the Nasdaq added 0.21%, according to Reuters. Those gains were much smaller than INVO’s move.
INVO’s next hurdle isn’t Friday’s action but filings. Investors are waiting on a 10-K and 10-Q for something concrete to value; if those don’t show, or if Nasdaq turns down the plan or results disappoint, the stock could be vulnerable after rallying fast.
